Market Analysis and Insights: Global Bladder Cancer Therapeutics and Diagnostics Market
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
The global Bladder Cancer Therapeutics and Diagnostics market size is projected to reach US$ 710.7 million by 2030, from US$ 433 million in 2022, at a CAGR of 6.9% during 2023-2030.
Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bladder Cancer Therapeutics and Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bladder Cancer Therapeutics and Diagnostics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bladder Cancer Therapeutics and Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bladder Cancer Therapeutics and Diagnostics market.
Global Bladder Cancer Therapeutics and Diagnostics Scope and Market Size
Bladder Cancer Therapeutics and Diagnostics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Bladder Cancer Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2030.
Segment by Type
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others
Segment by Application
- Hospitals
- Oncology Treatment Centers
- Ambulatory Surgery Centers
- Others
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
By Company
- Pfizer
- GlaxoSmithKline
- Merck
- Novartis
- Bristol-Myers Squibb
- Eli Lilly
- Roche
- Sanofi
- AstraZeneca
- Celgene Corporation
